{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:46:44Z","timestamp":1779925604385,"version":"3.53.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of end stage kidney disease (ESKD) and the clinical outcomes of patients with MPGN who commence kidney replacement therapy have not been comprehensively studied.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>All adult patients with ESKD due to glomerulonephritis commencing kidney replacement therapy in Australia and New Zealand from January 1, 1996 to December 31, 2016 were reviewed. Patients with ESKD due to MPGN were compared to patients with other forms of glomerulonephritis. Patient survival on dialysis and following kidney transplantation, kidney recovery on dialysis, time to transplantation, allograft survival, death-censored allograft survival and disease recurrence post-transplant were compared between the two groups using Kaplan Meier survival curves and Cox proportional hazards regression.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 56,481 patients included, 456 (0.8%) had MPGN and 12,660 (22.4%) had another form of glomerulonephritis. Five-year patient survival on dialysis and following kidney transplantation were similar between patients with ESKD from MPGN and other forms of glomerulonephritis (Dialysis: 59% vs. 62% <jats:italic>p<\/jats:italic>\u00a0=\u20090.61; Transplant: 93% vs. 93%, <jats:italic>p<\/jats:italic>\u00a0=\u20090.49). Compared to patients with other forms of glomerulonephritis, patients with MPGN had significantly poorer 5-year allograft survival (70% vs. 81% respectively, <jats:italic>p<\/jats:italic>\u00a0=\u20090.02) and death censored allograft survival (74% vs. 87%, respectively; <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.01). The risk of disease recurrence was significantly higher in patients with MPGN compared to patients with other glomerulonephritidites (18% vs. 5%; <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.01). In patients with MPGN who had allograft loss, patients with MPGN recurrence had a significantly shorter time to allograft loss compared to patients with MPGN who had allograft loss due to any other cause (median time to allograft loss 3.2\u2009years vs. 4.4\u2009years, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.01).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Compared with other forms of glomerulonephritis, patients with MPGN experienced comparable rates of survival on dialysis and following kidney transplantation, but significantly higher rates of allograft loss due to disease recurrence.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-019-1605-6","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T15:00:34Z","timestamp":1576508434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3571-6490","authenticated-orcid":false,"given":"Gregory J.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeoungjee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Teixiera-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Isbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"2","key":"1605_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.ajkd.2010.09.021","volume":"57","author":"JR Angelo","year":"2011","unstructured":"Angelo JR, Bell CS, Braun MC. Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis. 2011;57(2):291\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1605_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1605_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/ki.2010.1","volume":"77","author":"EC Lorenz","year":"2010","unstructured":"Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int. 2010;77(8):721\u20138.","journal-title":"Kidney Int"},{"issue":"4","key":"1605_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10157-017-1513-7","volume":"22","author":"N Nakagawa","year":"2018","unstructured":"Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H, et al. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2018;22(4):797\u2013807.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"1605_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.ki.5000084","volume":"69","author":"MA Little","year":"2006","unstructured":"Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 2006;69(3):504\u201311.","journal-title":"Kidney Int"},{"issue":"2","key":"1605_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1056\/NEJMoa013036","volume":"347","author":"EM Briganti","year":"2002","unstructured":"Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"1605_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-015-0219-x","volume":"17","author":"S Alasfar","year":"2016","unstructured":"Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol. 2016;17(1):7.","journal-title":"BMC Nephrol"},{"issue":"8","key":"1605_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00467-009-1322-7","volume":"25","author":"B Alchi","year":"2010","unstructured":"Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol Berl Ger. 2010;25(8):1409\u201318.","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"2","key":"1605_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1681\/ASN.2016020126","volume":"28","author":"MM O\u2019Shaughnessy","year":"2017","unstructured":"O\u2019Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC. Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol. 2017;28(2):632\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1605_CR10","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1097\/TP.0000000000000962","volume":"100","author":"M Pippias","year":"2016","unstructured":"Pippias M, Stel VS, Arest\u00e9-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, et al. Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry. Transplantation. 2016;100(9):1955.","journal-title":"Transplantation"},{"issue":"2","key":"1605_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.kint.2017.03.015","volume":"92","author":"PJ Allen","year":"2017","unstructured":"Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int. 2017;92(2):461\u20139.","journal-title":"Kidney Int"},{"issue":"8","key":"1605_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1\u201328.","journal-title":"J Stat Softw"},{"issue":"446","key":"1605_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"1605_CR14","volume-title":"A package for survival analysis in R [internet]","author":"TM Therneau","year":"2015","unstructured":"Therneau TM. A package for survival analysis in R [internet]; 2015."},{"key":"1605_CR15","volume-title":"survminer: drawing survival curves using \u201cggplot2\u201d","author":"A Kassambara","year":"2018","unstructured":"Kassambara A, Kosinski M. survminer: drawing survival curves using \u201cggplot2\u201d; 2018."},{"key":"1605_CR16","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2016","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016."},{"issue":"5","key":"1605_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1681\/ASN.2013070715","volume":"25","author":"L Zand","year":"2014","unstructured":"Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 2014;25(5):1110\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"1605_CR18","volume-title":"C3 Glomerulopathy","author":"B Mart\u00edn","year":"1993","unstructured":"Mart\u00edn B, Smith RJ. C3 Glomerulopathy. Seattle: GeneReviews; 1993."},{"issue":"s2","key":"1605_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(s2):61\u201380.","journal-title":"Liver Int"},{"key":"1605_CR20","volume-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement","author":"Hepatitis C Virus Infection Consensus Statement Working Group","year":"2018","unstructured":"Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Melbourne: Gastroenterological Society of Australia; 2018."},{"key":"1605_CR21","first-page":"239","volume":"31","author":"EA Bowie","year":"1989","unstructured":"Bowie EA, Collins JF, Doak PB, Gregory MC, North JDK, Richmond DE, et al. The New Zealand glomerulonephritis study: introductory report. Clin Nephrol. 1989;31:239\u201346.","journal-title":"Clin Nephrol"},{"issue":"3","key":"1605_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/ndt\/gfg592","volume":"19","author":"JH Stewart","year":"2004","unstructured":"Stewart JH, McCredie MRE, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in indigenous Australians. Nephrol Dial Transplant. 2004;19(3):678\u201385.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1605_CR23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2105\/AJPH.2005.070680","volume":"96","author":"L Ellison-Loschmann","year":"2006","unstructured":"Ellison-Loschmann L, Pearce N. Improving access to health care among New Zealand\u2019s Maori population. Am J Public Health. 2006;96(4):612\u20137.","journal-title":"Am J Public Health"},{"issue":"6","key":"1605_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1524-4733.2006.00130.x","volume":"9","author":"O Baser","year":"2006","unstructured":"Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9(6):377\u201385.","journal-title":"Value Health"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1605-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T01:58:45Z","timestamp":1605837525000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1605-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1605-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was granted by the Metro South Human Research Ethics Committee (HREC\/18\/QPAH\/153). All patients consented to be enrolled in the ANZDATA registry and the need to consent for this study was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"417"}}